An agnostic, host-direct survival cure MCM for pulmonary toxicants. - pulmonary exposure to chemical warfare agents (CWA), or to industrial pulmonary toxicants (IPT) is a serious unmet medical…
Ended Project Grant Awarded Last action
- Award ID
- R44AI186862
- Recipient
-
Xfibra, Inc. UEI D26NRF445JV3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,999,202
Award facts
- Assistance listing
- 93.310 Trans-NIH Research Support
- Completion date
- Funding agency
- Office of the Director National Institutes of Health, Department of Health and Human Services
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
An agnostic, host-direct survival cure MCM for pulmonary toxicants. - pulmonary exposure to chemical warfare agents (CWA), or to industrial pulmonary toxicants (IPT) is a serious unmet medical challenge that impacts the safety of our nation's civilian population and armed forces that could result in high morbidity and mortality. Effective medical countermeasures (MCM) are not available to treat pulmonary exposure to CWA or to IPT that threaten the lives of civilians and military personnel. We have developed XFB19, a first-in-class, homeostatic, direct anti-inflammatory, anti-fibrotic interference peptide against the THR266 phosphorylation site of human c/ebpβ, with outstanding efficacy in models of CWA (sulfur mustard), acute respiratory distress syndrome (sulfur mustard, bleomycin), and idiopathic pulmonary fibrosis (bleomycin). XFB19 has an excellent safety and efficacy profile in pre-clinical studies. The aims of this sbir direct to phase 2 will facilitate the development of XFB19 as an MCM for pulmonary toxicants, as well as a treatment for acute respiratory distress syndrome and idiopathic pulmonary fibrosis.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $999,601 | |
| Original award | $999,601 |
Quick answers
Who received award R44AI186862?
R44AI186862 was awarded to Xfibra, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 1, 2024.
How much is award R44AI186862 worth?
$1,999,202 has been obligated on R44AI186862.
Which agency awarded R44AI186862?
National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded R44AI186862, with funding from Office of the Director (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award